10x Genomics Inc. (TXG)
NASDAQ
Real-time Data
01:30 PM
Day's Range
61.7552 wk Range
11.16Overview - TXG - 10x Genomics Inc.
Key Statistics
Valuation
Enterprise Value
8.01B
P/E (Trailing)
‪-186.01‬
P/E (Forward)
‪320.26‬
PEG Ratio
‪1.24‬
Price / Sales (TTM)
‪13.75‬
Price / Book
‪10.31‬
EV / EBITDA
‪-194.44‬
Profitability
Gross Margin
‪74.48%‬
Profit Margin
‪-12.17%‬
Operating Margin
‪-15.19%‬
Return on Assets
‪-5.04%‬
Return on Equity
‪-9.39%‬
Ownership
Shares Outstanding
130.28M
Float
118.18M
Short % of Shares Outstanding
‪17.59%‬
Held by Insiders
‪1.59%‬
Held by Institutions
‪112.02%‬
Price stats
Beta
‪2.03‬
50-Day Avg
‪44.77‬
200-Day Avg
‪26.56‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
16 analysts
Average price target
‪$ 49.54‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - TXG - 10x Genomics Inc.
Peers - TXG - 10x Genomics Inc.
Peer Comparison
Compared with companies in Health Information Services listed on NASDAQ.
Profile Summary - TXG - 10x Genomics Inc.
About
10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems globally. The company specializes in single cell and spatial biology, enabling researchers to study individual cells and understand complex biological processes at unprecedented resolution. Its primary platforms…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
